Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000;27:390-401.
Centers for disease control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting-United States. Ann Intern Med 1985;103:402-403.
Levine AM, Meyer PR, et al. Development of B-cell lymphoma in homosexual men: clinical and immunologic finding. Ann Intern Med 1984;100:7-13.
Ziegler JL, Beckstead JA. Non-Hodgkin’s lymphoma in 90 homosexual men. N Engl J Med 1984;31:565-570.
Levine AM. Acquired immunodeficiency syndrome-related lymphoma. Blood 1992;80:8-20.
Kalter SP, Riggs SA, et al. Aggressive non-Hodgkin’s lymphoma in immunocompromised homosexual males. Blood 1985;66:655-659.
Knowles DM, Chamulak GA. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1988;108:744-753.
Kaplan LD, Abrams DI. AIDS associated non-Hodgkin’s lymphoma in san Francisco. JAMA 1989;261(5):719-724.
Grabar S, Le Moing V, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000;133:401-403.
Kaplan LD, Straus DJ. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997;336:1641-1648.
Levine AM. Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 2000;27:442-453.
Sparano JA, Wiemik PH. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgastrim in patients with human immunodeficiency virus-associated non-Hodgkin’s lymphoma. J Clin Oncol 1996;14:3026-3035.
Ratner L, Lee J. Chemotherapy for human immunodeficiency virusassociated non-Hodgkin’s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171-2178.
N’ Galy B, Bertozzi S. Obstacles to the optimal management of HIV infection/AIDS in Africa. J Acquir Immune Defic Syncir 1990;3:430-437.
B. Borisch, M.Raphael, SH. Swerdlow. Lymphoproliferative diseases associated with primary immune disorders. En: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Jaffe E.S, Harris N.L, Stein H, Vardiman J.W. IARC press: Lyon 2001. p. 257-263.
Rosenberg SA. Validity of the Ann Arbor Staging Classification for the Non- Hodgkin’s Lymphomas. Cancer Treat Rep 1977;61:1023-1027.
Armitage JO, Weisenburger DD. New Approach to classifying non-Hodgkin’s Lymphoma: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 1998;16:2780-2795.
World Health Organization. Common toxity criteria (CTC). 30 April 1999. p. 8-10.
Kazunori Ohnishi. Current trends in the management of malignant lymphoma: new WHO classification, guidelines for high-dose therapy with HSCT, and new response criteria. Int J Clin Oncol 2000;5:1-7.
Centers for Disease control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome.MMWR.1987;36(suppl1S)1S-15S.
Alexandra M. Levine, Lasika Seneviratne. Evolving characteristics of AIDS-related lymphoma. Blood 2000;96:4084-4090.
Tulpule A, Sherrod A, Dharmapala et al. Multidrug resistance (MDR-1) expression in aids-related lymphomas Leuk Res 2002;26:121-127.
Richard F. little, Stefania Pittaluga. Highly effective treatment of acquired immunodeficiency syndrome- related lymphoma with dose adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-4659.
Besson C, Goubar A, Gabarre J et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood 2001;98:2339-2344.
Caroline Besson, Aicha Goubar. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344.
Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy Aids 2001;15:1483-1491.
Ledergerber B, Telenti A, Effer M. Risk of HIV related Kaposi’s sarcoma and non-Hodgkin’s lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J 1999;319:23-24.
Rabkin CS, Testa MA, Fischl MA, et al. Declining incidence of Kaposi’s sarcoma in AIDS clinical trial group (ACTG) trials(abstract S4). J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:A39.
Jacobson LP. Impact of highly effective anti-retroviral therapy on the incidence of malignancies among HIV-infected individual (abstract S5). J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:A39.
Romeu J, Navarro T, Tural C, et al. Effect of HAART on response to therapy and survival in patients with AIDS-related non-Hodgkin’s lymphoma(abstract TuPeB3162). Program and abstracts of the XIII International AIDS; Durban, South Africa 2000:9-14.
Caroline Besson, Aicha Goubar. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy Blood 2001;98:2339-2344.
Centers for Disease control and prevention. Update: AIDS among women-United States,1994.MMWR. 1995;44:81-84.
Hernández-Rivera G, Gómez Roel X, Villasís-Keever. Linfomas nohodgkin asociados a SIDA: 1) evolución de los 20 años de la pandemia.2) experiencia en el INCMNSZ. Rev Invest Clin 2004;56(2):186-192.